Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.
Remo Holanda de Mendonça FurtadoItamar RazErica L GoodrichSabina A MurphyDeepak L BhattLawrence Alan LeiterDarren K McGuireJohn P H WildingPhilip AylwardAnthony J DalbyMikael DellborgDoina DimulescuJose Carlos NicolauAnthonius J M Oude OphuisAvivit CahnOfri MosenzonIngrid Gause-NilssonAnna Maria LangkildeMarc S SabatineStephen D WiviottPublished in: Circulation (2022)
gov; Unique identifier: NCT01730534.